Daiichi Sankyo Looks To Increase Sales To ¥1.15 Trillion In Three Years
This article was originally published in PharmAsia News
Executive Summary
Aiming to generate new revenues from its generic drug and vaccine businesses and expand shares in emerging markets, Daiichi Sankyo revealed a new three year plan and a goal of ¥1.15 trillion ($12.7 billion) in sales by 2012